Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b study of R2891, a potent and ...
Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to ...
Servier today announced that it will present new and updated data at the 67th Annual Meeting of the American Society of Hematology (ASH), December 6-9, 2025, in Orlando, Florida. Presentations will ...
Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...
Use of point-of-care ultrasound in prehospital settings: clinical applications and future directions
Point-of-care ultrasound (POCUS) involves performing US examinations directly at the point of patient care in both prehospital and hospital settings.1,2 POCUS involves using US diagnostics by medical ...
Oversteyns, N. , Puydt, H. and Vandervelden, S. (2025) Chloramine Intoxication in a Five-Month Pregnant Patient: A Case Report. Case Reports in Clinical Medicine, 14, 628-634. doi: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback